4D Molecular Therapeutics, Inc. (FDMT) stock
FDMTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/302% above fair value
$12.12−0.88 (-6.74%)
Close on Nov 12, 2026Market cap $874.46MP/E –Yield –
4D Molecular Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
4D Molecular Therapeutics's enterprise value was $375.48M on Nov 11, 2026, against $240.29M a year earlier. Over the last 5 years it ranged from -$276.96M to $1.08B, with a median of $224.53M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $375.48M | +721.3% |
| 2025 | Dec 31, 2025 | $45.72M | – |
| 2024 | Dec 31, 2024 | -$212.27M | -138.8% |
| 2023 | Dec 29, 2023 | $546.50M | +11.1% |
| 2022 | Dec 30, 2022 | $491.72M | -2.6% |
| 2021 | Dec 31, 2021 | $505.02M | +206.0% |
| 2020 | Dec 31, 2020 | $165.02M | – |
See a number that looks wrong?